Q-omics provides the consensus-scored LINC02210-CRHR1 profile across patient tissues and cancer cell-line models. LINC02210-CRHR1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, LINC02210-CRHR1 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, LINC02210-CRHR1 RNA expression shows 6,537 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LGG, THCA, and STAD as cancer lineages where LINC02210-CRHR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02210-CRHR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02210-CRHR1 survival associations across molecular data types. LINC02210-CRHR1 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02210-CRHR1 RNA expression–survival associations across cancer types. High LINC02210-CRHR1 expression shows unfavorable associations in KIRP, LUSC, LAML and LIHC, but favorable associations in LGG and KIRC. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for LINC02210-CRHR1 RNA expression.
This table summarizes LINC02210-CRHR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02210-CRHR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02210-CRHR1 shows lower tumor expression in THCA and higher tumor expression in BLCA and LUAD. The THCA box plot shows higher LINC02210-CRHR1 RNA expression in normal versus tumor tissue (log2 FC = −0.140, t-test p = .001).
This table shows molecular features associated with LINC02210-CRHR1 in patient tissues and cancer cell lines. In patient samples, LINC02210-CRHR1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
